Amgen 거래 AMGN

매도
 매수

Amgen 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

최신 뉴스

Frances Wang 2025 Apr 09, 16:00

Stock indices today: Nikkei 225 Rebounds After Yen Weakens Against Dollar

Indices
Tommy Yap 2025 Apr 09, 16:00

Morning Note: Trump Tariff U-Turn, US Inflation Awaited, Japan PPI Up

Morning Note
Frances Wang 2025 Apr 08, 16:00

GME Stock Price: what’s the risks and challenges ahead of GME stock?

Stocks
Tommy Yap 2025 Apr 08, 16:00

Morning Note: RBNZ Rate Cut, Oil Slide, Musk's Tariff Clash

Morning Note Oil
Frances Wang 2025 Apr 07, 16:00

Stock Market Today: Dow, S&P 500 Drop, Nasdaq Rises in Volatile Session

Indices Stocks
Tommy Yap 2025 Apr 07, 16:00

Morning Note: Trade Fears Hit Nvidia, Deepen US-China Clash; UK Seeks US Deal

Morning Note USD China
Frances Wang 2025 Apr 06, 16:00

Monthly Economic Report: Insights into Growth and Trends

Fed
Tommy Yap 2025 Apr 06, 16:00

Morning Note: Markets Tumble on Tariffs, Bitcoin Below $80K & Yen Gains

Morning Note Cryptocurrencies Forex

정보

스프레드

2.26

스프레드(%)

0.8061 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 개장

목요일

13:31 - 19:59

월요일

13:31-19:59

화요일

13:31-19:59

수요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

158147788800

발행 주식 수

537204992

수익 날짜 (다음)

1999-11-22

배당수익률

2025-06-06

배당락일

2025-05-16

예상 연간 배당금

9.52

예상 연간 배당수익률

0.0323

EPS

7.57

이 상품에 대해 자세히 알아보기

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments
Trustpilot